Benjamin Oakes, Scribe Therapeutics CEO

CEO of Doud­na spin­out: With­in five years, genome ed­i­tors will have a 're­al­ly big im­pact' on pa­tients' lives

“CRISPR-by-de­sign” is the idea be­hind Scribe Ther­a­peu­tics, a com­pa­ny spun out from Jen­nifer Doud­na’s No­bel-win­ning lab that’s com­pet­ing in a close­ly-tracked field of genome ed­i­tor …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.